Danish film star in Inferno

Sidse Babett Knudsen, a Danish actress mostly known for her role in the popular TV series 'Borgen', will star alongside Tom Hanks in the third film adaptation of Dan Brown's Robert Langdon series.

Knudsen will play the role of Elizabeth Sinskey, a powerful leader at the UN Health Organization, in the mystery thriller 'Inferno'.

Tom Hanks will return as the main character, symbologist Robert Langdon, as in the two previous adaptations of Brown's novels: 'The Da Vinci Code' and 'Angels and Demons'.

The film will once again be directed by Ron Howard and is scheduled to premiere on 13 October 2016. 

Danes acting in Brown's adaptations
It is not the first time that a Danish actor has been involved in one of Dan Brown's screen adaptations.

Thura Lindhardt and Nikolaj Lie Kaas both appeared in 'Angels and Demons', which premiered in 2009.





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.